| SYBX Synlogic | $1.77 -48.7%
 | 2/9/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 | 
| AMGN Amgen | $291.12 -1.3%
 | 2/7/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 2/7/2024 | 
| UTHR United Therapeutics | $212.34 +0.3%
 | 2/5/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform |  | Low | View details for Leerink Partnrs rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 | 
| TSVT 2seventy bio | $5.99 
 | 1/31/2024 | Upgraded by | Leerink Partnrs | Analyst D. Graybosch | Market Perform -> Outperform |  | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024 | 
| NPCE NeuroPace | $16.41 -3.0%
 | 1/30/2024 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform |  | Low | View details for Leerink Partnrs rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 | 
| IMNM Immunome | $23.11 -1.6%
 | 1/29/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform |  | Low | View details for Leerink Partnrs rating of Immunome (NASDAQ:IMNM) on 1/29/2024 | 
|  | 
| PYXS Pyxis Oncology | $4.48 +20.8%
 | 1/23/2024 | Reiterated by | Leerink Partnrs | Analyst J. La. Rosa | Outperform |  | Low | View details for Leerink Partnrs rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 | 
| HARP Harpoon Therapeutics | $22.45 +0.5%
 | 1/8/2024 | Downgraded by | Leerink Partnrs | Analyst J. Chang | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Harpoon Therapeutics (NASDAQ:HARP) on 1/8/2024 | 
| AGL agilon health | $6.82 -3.8%
 | 1/8/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of agilon health (NYSE:AGL) on 1/8/2024 | 
| KRTX Karuna Therapeutics | $317.14 +0.3%
 | 12/22/2023 | Downgraded by | Leerink Partnrs | Analyst M. Goodman | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Karuna Therapeutics (NASDAQ:KRTX) on 12/22/2023 | 
| ALVR AlloVir | $0.72 +7.0%
 | 12/22/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 | 
| WVE Wave Life Sciences | $4.10 +1.0%
 | 12/19/2023 | Upgraded by | Leerink Partnrs | Analyst J. Schwartz | Market Perform -> Outperform |  | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 | 
| NBTX Nanobiotix | $7.39 -1.6%
 | 12/8/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform |  | Low | View details for Leerink Partnrs rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 | 
| TRML Tourmaline Bio | $36.75 +1.4%
 | 12/7/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform |  | Low | View details for Leerink Partnrs rating of Tourmaline Bio (NASDAQ:TRML) on 12/7/2023 | 
| MOR MorphoSys | $17.15 
 | 12/6/2023 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Market Perform |  | Low | View details for Leerink Partnrs rating of MorphoSys (NASDAQ:MOR) on 12/6/2023 | 
| TNYA Tenaya Therapeutics | $5.68 +10.7%
 | 11/30/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform |  | Low | View details for Leerink Partnrs rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 | 
| LXEO Lexeo Therapeutics | $16.54 -1.7%
 | 11/28/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform |  | Low | View details for Leerink Partnrs rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 | 
| ABVX ABIVAX Société Anonyme | $12.50 -2.1%
 | 11/14/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform |  | Low | View details for Leerink Partnrs rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 | 
| ACRS Aclaris Therapeutics | $1.23 +4.2%
 | 11/13/2023 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/13/2023 | 
| ZNTL Zentalis Pharmaceuticals | $11.50 -0.3%
 | 11/7/2023 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 | 
| MRTX Mirati Therapeutics | $58.70 -0.2%
 | 11/7/2023 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Mirati Therapeutics (NASDAQ:MRTX) on 11/7/2023 | 
| TSVT 2seventy bio | $5.99 
 | 10/30/2023 | Downgraded by | Leerink Partnrs | Analyst D. Graybosch | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 | 
| BEAM Beam Therapeutics | $29.05 +3.3%
 | 10/20/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 | 
| OLK Olink Holding AB (publ) | $24.22 -0.6%
 | 10/17/2023 | Downgraded by | Leerink Partnrs | Analyst P. Souda | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Olink Holding AB (publ) (NASDAQ:OLK) on 10/17/2023 | 
| FDMT 4D Molecular Therapeutics | $28.63 +6.4%
 | 10/18/2023 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Market Perform -> Outperform |  | Low | View details for Leerink Partnrs rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 | 
| PLRX Pliant Therapeutics | $16.93 +3.9%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform |  | Low | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 10/16/2023 | 
| MORF Morphic | $39.70 +2.6%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform |  | Low | View details for Leerink Partnrs rating of Morphic (NASDAQ:MORF) on 10/16/2023 | 
| KYMR Kymera Therapeutics | $37.21 +9.5%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Market Perform |  | Low | View details for Leerink Partnrs rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/16/2023 | 
| VCEL Vericel | $46.78 +2.0%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform |  | Low | View details for Leerink Partnrs rating of Vericel (NASDAQ:VCEL) on 10/16/2023 | 
| TNDM Tandem Diabetes Care | $23.30 +0.6%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform |  | Low | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 | 
| SWAV Shockwave Medical | $233.71 -1.3%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform |  | Low | View details for Leerink Partnrs rating of Shockwave Medical (NASDAQ:SWAV) on 10/16/2023 | 
| PRCT PROCEPT BioRobotics | $49.94 +0.9%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform |  | Low | View details for Leerink Partnrs rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 | 
| PODD Insulet | $192.55 -2.1%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform |  | Low | View details for Leerink Partnrs rating of Insulet (NASDAQ:PODD) on 10/16/2023 | 
| INSP Inspire Medical Systems | $194.87 -3.5%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform |  | Low | View details for Leerink Partnrs rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 | 
| EW Edwards Lifesciences | $85.01 -0.9%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform |  | Low | View details for Leerink Partnrs rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 | 
| DXCM DexCom | $120.47 -5.2%
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform |  | Low | View details for Leerink Partnrs rating of DexCom (NASDAQ:DXCM) on 10/16/2023 | 
| AXNX Axonics | $67.95 
 | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform |  | Low | View details for Leerink Partnrs rating of Axonics (NASDAQ:AXNX) on 10/16/2023 | 
| GILD Gilead Sciences | $73.67 -0.2%
 | 10/11/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform |  | Low | View details for Leerink Partnrs rating of Gilead Sciences (NASDAQ:GILD) on 10/11/2023 | 
| AMGN Amgen | $291.12 -1.3%
 | 10/11/2023 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Market Perform -> Outperform |  | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 10/11/2023 | 
| ACLX Arcellx | $64.89 +5.4%
 | 10/12/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Outperform |  | Low | View details for Leerink Partnrs rating of Arcellx (NASDAQ:ACLX) on 10/12/2023 | 
|  | 
| SPRY ARS Pharmaceuticals | $7.08 +9.1%
 | 9/21/2023 | Downgraded by | Leerink Partnrs | Analyst R. Ruiz | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 | 
| TSBX Turnstone Biologics | $2.16 -2.3%
 | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform |  | Low | View details for Leerink Partnrs rating of Turnstone Biologics (NASDAQ:TSBX) on 8/15/2023 | 
| GLTO Galecto | $0.62 +1.5%
 | 8/15/2023 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Galecto (NASDAQ:GLTO) on 8/15/2023 | 
| DSGN Design Therapeutics | $2.32 +1.3%
 | 8/15/2023 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform |  | Low | View details for Leerink Partnrs rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 | 
| CYTK Cytokinetics | $76.94 -2.5%
 | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform |  | Low | View details for Leerink Partnrs rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 | 
| RLAY Relay Therapeutics | $9.09 +2.2%
 | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform |  | Low | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 | 
| NUVL Nuvalent | $82.45 +2.3%
 | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform |  | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 | 
| IDYA IDEAYA Biosciences | $45.89 +2.4%
 | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform |  | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 | 
| EXEL Exelixis | $20.22 +0.2%
 | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform |  | Low | View details for Leerink Partnrs rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 | 
| QTRX Quanterix | $24.28 -0.3%
 | 8/8/2023 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Market Perform -> Outperform |  | Low | View details for Leerink Partnrs rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 | 
| NVCR NovoCure | $15.31 +3.1%
 | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform |  | Low | View details for Leerink Partnrs rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 | 
| WVE Wave Life Sciences | $4.10 +1.0%
 | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Market Perform |  | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 8/4/2023 | 
| BLTE Belite Bio | $47.55 +3.7%
 | 7/26/2023 | Reiterated by | Leerink Partnrs | Analyst M. Goodman | Outperform |  | Low | View details for Leerink Partnrs rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |